Edition:
India

Astrazeneca Pharma India Ltd (ASTR.NS)

ASTR.NS on National Stock Exchange of India

2,064.40INR
3:56pm IST
Change (% chg)

Rs53.80 (+2.68%)
Prev Close
Rs2,010.60
Open
Rs2,045.00
Day's High
Rs2,078.00
Day's Low
Rs2,015.00
Volume
12,710
Avg. Vol
18,703
52-wk High
Rs2,397.70
52-wk Low
Rs1,306.05

Latest Key Developments (Source: Significant Developments)

Astrazeneca Pharma India June-Qtr Profit Rises
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Astrazeneca Pharma India Ltd ::JUNE QUARTER PROFIT 215.2 MILLION RUPEES VERSUS PROFIT OF 63.9 MILLION RUPEES LAST YEAR.JUNE QUARTER REVENUE FROM OPERATIONS 2.05 BILLION RUPEES VERSUS 1.61 BILLION RUPEES LAST YEAR.  Full Article

Astrazeneca Pharma Receives Import, Market Permission For Osimertinib Tablet
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Astrazeneca Pharma India Ltd ::ASTRAZENECA PHARMA INDIA -GOT IMPORT, MARKET PERMISSION IN FORM 45 FROM DRUGS CONTROLLER GENERAL OF INDIA FOR OSIMERTINIB TABLET 40 MG,80 MG.ASTRAZENECA PHARMA INDIA LTD - OSIMERTINIB TABLET INDICATED FOR FIRST-LINE TREATMENT OF CERTAIN NON-SMALL CELL LUNG CANCERS.  Full Article

Astrazeneca Pharma India says FDC Of XIGDUO XR Tablets Expected To Launch In India In Q4
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Astrazeneca Pharma India Ltd ::FDC OF DAPAGLIFLOZIN + METFORMIN HYDROCHLORIDE FILM COATED TABLETS EXPECTED TO LAUNCH IN INDIA IN Q4 2017-18.  Full Article

Astrazeneca Pharma India Sept-qtr profit surges
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Astrazeneca Pharma India Ltd ::Sept quarter profit 273.8 million rupees.Sept quarter revenue from operations 1.64 billion rupees.Profit in sept quarter last year was 8 million rupees as per ind-as; revenue from operations was 1.39 billion rupees.  Full Article

Astrazeneca Pharma India gets marketing approval for combination of therapies for type 2 diabetes‍​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Astrazeneca Pharma India Ltd ::Gets marketing approval for Xigduo XR, combination of two anti-diabetic therapies for type 2 diabetes‍​.  Full Article